Previous 10 |
Ligand Pharmaceuticals (NASDAQ: LGND ) is scheduled to announce Q4 earnings results on Thursday, February 7th, after market close. More news on: Ligand Pharmaceuticals Incorporated, Earnings news and commentary, , Healthcare stocks news, Read more ...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces closing an investment in Dianomi Therapeutics, Inc., a biopharmaceutical company focused on improving the delivery and efficacy of large and small molecules in the treatment of a variety of diseases and on therapies for inflammat...
NEW YORK, Feb. 01, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Micron Technology, Inc. (NASDAQ:MU), Quidel Corporation (NASDAQ:QDEL), Li...
Seelos Therapeutics was a privately held biopharmaceutical company that recently finalized a reverse merger with Apricus Biosciences "APRI". This merger now allows Seelos to become a public traded company without going through the hassle of an IPO. The combined company is now trading under the...
Proceeds from financing completed simultaneously with reverse merger to be used to fund pipeline which includes programs licensed from Ligand Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Seelos Therapeutics, Inc. (NASDAQ: SEEL) announced that it has closed a reverse me...
NEW YORK, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) diso...
Goldman Sachs analyst Dana Flanders provides the numbers behind his Street-low fair value target of $168 (46% upside) for Ligand Pharmaceuticals ( LGND -2.1% ) which makes money via licensing deals. More news on: Ligand Pharmaceuticals Incorporated, Healthcare stocks news, Stocks on the ...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
2024-07-30 06:30:09 ET RBC Capital analyst issues OUTPERFORM recommendation for LGND on July 30, 2024 03:16AM ET. LGND was trading at $108.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy recomm...
2024-07-30 06:00:04 ET Douglas Miehm from RBC Capital issued a price target of $130.00 for LGND on 2024-07-30 03:16:00. The adjusted price target was set to $130.00. At the time of the announcement, LGND was trading at $108.75. The overall price target consensus is at $1...
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial resul...